BioAge Labs, Inc.

BIOA

Held by 1 specialist biotech fund

Share on X

Fund Holdings

OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management3.7%Feb 14, 2025

SC 13GRA Capital Management6.2%Oct 7, 2024

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 790,901Value: $10.5M

# Signal Note: OrbiMed Initiates $10.5M Position in BioAge Labs **Why it matters:** OrbiMed's entry signals confidence in BioAge's longevity platform, which targets aging-related diseases through epigenetic biomarkers and cellular reprogramming—a space showing clinical momentum following recent partial reprogramming data in human studies. The $10.5M stake (790,901 shares) from one of healthcare's most selective allocators suggests institutional validation ahead of near-term clinical readouts, likely catalysts including IND-enabling studies or aging biomarker partnerships with pharma.

More BIOA Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS1 fund RNA1 fund IRON1 fund ANRO1 fund FOLD1 fund BCAX1 fund ARGX1 fund PRAX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: